Company intelligence
BioCentury Inc.
About BioCentury Inc.
BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com
Verified activity
Signals from BioCentury Inc.
13 published signals
Presence & Recognition
BioCentury Inc. and BayHelix are attending two Asia-focused summits, China Healthcare Summit in Shanghai on November 2–4, 2026, and East-West Biopharma Summit in Seoul on March 15–17, 2027.
Reported by BioCentury Inc.
Presence & Recognition
BioCentury Inc. is hosting the BioCentury Grand Rounds in Amsterdam from September 23 to 25, 2026, featuring the Poster Sessions to showcase early-stage science and technology with commercial potential.
Reported by BioCentury Inc.
Presence & Recognition
BioCentury Inc. is hosting the BioCentury Grand Rounds in Europe for three days in Amsterdam from September 23 to 25, 2026, with limited-time savings for new registrations.
Reported by BioCentury Inc.
Research & Knowledge
BioCentury Inc. published its annual Pharma Deal Analysis finding that deals by 21 top pharmaceuticals in the past 12 months are clustering in breakthrough new technologies.
Reported by BioCentury Inc.
Research & Knowledge
BioCentury Inc. released an annual pharma deals report by Lauren Martz.
Reported by Matt Krebs
Research & Knowledge
BioCentury Inc. ran its annual pharma deals report through its newly launched BioCentury AI Connectors.
Reported by Matt Krebs
Research & Knowledge
BioCentury Inc. reported that Stephen Hansen dives into the Menarini obesity deal in his recent BioCentury Inc. report.
Reported by Matt Krebs
Research & Knowledge
BioCentury Inc. Director of Research Meredith Durkin Wolfe maps the September regulatory calendar and the companies to watch.
Reported by BioCentury Inc.
Presence & Recognition
BioCentury Inc. published an article examining the litigation, implementation, and industry risks surrounding the major-favored-nation strategy, Lilly's 13th takeout of the year, and Heidi Overton's path toward FDA on the latest BioCentury This Week.
Reported by BioCentury Inc.
Research & Knowledge
BioCentury Inc. published its 34th Back to School report examining the global race to accelerate first-in-human trials and how early clinical development is being rethought across countries such as China, Australia, the U.K., Denmark, Spain, and the U.S.
Reported by BioCentury Inc.
Products & Services
BioCentury Inc. launched BioCentury AI Connectors for BD, regulatory, and clinical teams to interrogate more than 30 years of BioCentury analysis directly inside AI tools.
Reported by BioCentury Inc.
Presence & Recognition
BioCentury Inc. is hosting an exclusive Leiden BioScience Park tour for registered delegates on September 23–25, 2026.
Reported by BioCentury Inc.
Research & Knowledge
BioCentury Inc. colleague Lindsay Martin, PhD talks to Martin Babler and Jörn Drappa and others to break down the data, the subgroup signal, and what comes next regarding the TYK2 inhibitor miss pushing Alumis toward precision strategy for lupus
Reported by Matt Krebs